
    
      Patients will receive (an) infusion(s) of in vitro cultured islets with the goal of achieving
      insulin independence. For the first islet transplant, patients will receive induction therapy
      with rabbit anti-thymocyte globulin (ATG, 5 doses) and will remain on their maintenance
      immunosuppression regimen already in place for their renal allograft. Induction therapy for
      subsequent transplants will be 2doses of basiliximab.

      All patients will receive Etanercept to promote engraftment.
    
  